Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status

Inclusion criteria

• Participant must be ≥18 years of age
• The study enrolls healthy participants and participants at different stages of renal impairment (mild to severe renal impairment).
• Race: White
• BMI (body mass index): above or equal 18.5 and below or equal 35 kg/m*2 at the first screening visit.
• Male or female.
• Participants with renal impairment must have an eGFR (estimated glomerular filtration rate) <90 mL/min/1.73 m*2 determined from serum creatinine 21-3 days prior to dosing using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation (eGFR has to be repeated if screening period >10 days before dosing).

Stable renal function, e.g. a serum creatinine value determined at least 3 months before the pre-study visit should not vary by more than 25% from the serum creatinine value determined at the pre-study visit confirmed by nephrologist or general practitioner the patient is under care.

Exclusion criteria

• Clinically relevant findings in the physical examination affecting the objectives of the study.
• Systemic use of the following co-medications from 2 weeks before administration until end of follow-up:

• Moderate and strong inhibitors of CYP3A;
• Moderate and strong CYP3A inducers;
• Moderate and strong inhibitors of P-gp transport;
• UDP-glucuronosyltransferase (UGT) inhibitors probenecid and valproic acid.
• Regular daily consumption of more than 10 cigarettes.
• Acute renal failure.
• Active nephritis.
• Impairment of any other major organ system other than the kidney.
• Change in chronic medications for renal disease (or its consequences) less than 4 weeks prior to dosing.